Qilu Pharmaceutical Co., Ltd.: clinical-trial pipeline
Qilu Pharmaceutical Co., Ltd. is the sponsor of 196 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 102 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 71 |
| Phase 3 | 59 |
| Phase 2 | 32 |
| Phase 1/2 | 18 |
| Phase 2/3 | 8 |
| Not applicable | 6 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 62 |
| Not yet recruiting | 60 |
| Recruiting | 37 |
| Completed | 31 |
| Active, not recruiting | 5 |
| Terminated | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 112 |
| Cardiovascular | 16 |
| Gastroenterology and liver | 16 |
| Immunology and rheumatology | 14 |
| Infectious disease and vaccines | 14 |
| Haematology | 13 |
| Nephrology and urology | 12 |
| Women's health and obstetrics | 10 |
| Dermatology | 8 |
| Neurology | 6 |
| Ophthalmology | 6 |
| Musculoskeletal | 5 |
Countries
| Country | Trials |
|---|---|
| China | 139 |
| Poland | 2 |
| Bosnia & Herzegovina | 1 |
| Germany | 1 |
| Spain | 1 |
| United Kingdom | 1 |
| Georgia | 1 |
| Greece | 1 |
| Hungary | 1 |
| India | 1 |
| New Zealand | 1 |
| Romania | 1 |
| Thailand | 1 |
| Ukraine | 1 |
| Vietnam | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-06 | New trial posted | Comparative Study of QL1209 and Perjeta® in Healthy Male Participants |
| 2026-09-21 | New trial posted | Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Met… |
| 2026-09-03 | New trial posted | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-ba… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Active, not recruiting | Bosnia & Herzegovina, China, Spain, Georgia +8 |
| 2025-523355-59-00 | A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamic… | Phase 1 | Not yet recruiting | Poland |
| NCT07400744 | A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects | Phase 1 | Not yet recruiting | |
| NCT07173595 | A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies | Phase 1 | Recruiting | China |
| NCT06799559 | Study on the Efficacy and Safety of QLM1016 in Schizophrenia | Phase 3 | Active, not recruiting | China |
| NCT06911827 | A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | Phase 1/2 | Recruiting | China |
| NCT07489586 | A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration | Phase 3 | Not yet recruiting | |
| NCT07294300 | A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies | Phase 1 | Not yet recruiting | China |
| NCT07730632 | Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) | Phase 2 | Not yet recruiting | China |
| NCT07511647 | A Phase 3 Clinical Study of QL2106 Injection | Phase 3 | Active, not recruiting | China |
| NCT06823609 | Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors | Phase 1 | Recruiting | China |
| NCT06261359 | A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | China |
| NCT07104110 | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | Phase 1/2 | Not yet recruiting | |
| NCT06932094 | Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors | Phase 1 | Not yet recruiting | China |
| NCT07124468 | Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Praluba… | Phase 1 | Recruiting | China |
| NCT06456528 | QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | Phase 2/3 | Recruiting | China |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | Phase 3 | Not yet recruiting | |
| NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | Phase 1 | Not yet recruiting | |
| NCT06500507 | A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | China |
| NCT05690945 | A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer | Phase 3 | Active, not recruiting | China |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With A… | Phase 1/2 | Recruiting | China |
| NCT06872580 | A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors | Phase 1 | Not yet recruiting | |
| NCT07062978 | A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | Phase 3 | Recruiting | China |
| NCT07489599 | A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's… | Phase 1 | Not yet recruiting | |
| NCT07079228 | A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Ca… | Phase 3 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Qilu Pharmaceutical Co., Ltd. clinical trials: 102 open, 67 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/qilu-pharmaceutical-co-ltd/, data as of 2026-10-25.